4.8 Article

Remotely Ameliorating Blood Glucose Levels in Type 2 Diabetes Via a Near-Infrared Laser

Journal

ADVANCED FUNCTIONAL MATERIALS
Volume 31, Issue 8, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.202007215

Keywords

AKT signaling pathways; glucose metabolic regulation; optogenetics; type 2 diabetes; upconversion nanoparticles

Funding

  1. National Key Research and Development Program of China [2017YFE0131700]
  2. National Natural Science Foundation of China [21874096]
  3. Collaborative Innovation Center of Suzhou Nano Science and Technology
  4. 111 Project
  5. Joint International Research Laboratory of Carbon-Based Functional Materials and Devices
  6. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

Ask authors/readers for more resources

A new therapeutic approach utilizing near-infrared laser to remotely control glucose metabolism for the treatment of type 2 diabetes has been proposed and successfully demonstrated in vitro and in vivo. By integrating fluorescent upconversion nanoparticles with optogenetic technique, this method selectively activates specific signaling pathways for insulin-independent treatment, providing potential new alternative strategies for managing type 2 diabetes clinically.
Type 2 diabetes, lowly responsive to insulin injection, is a difficult chronic disease which requires therapeutic breakthroughs. Herein, a new concept is proposed to remotely control the glucose metabolism by a near-infrared (NIR) laser for the treatment of type 2 diabetes for the first time. This method integrates fluorescent upconversion nanoparticles with the optogenetic technique to selectively activate the phosphoinositide 3-kinase/AKT signaling pathways, in an insulin-independent manner for type 2 diabetic treatments. It features fast responsiveness (in seconds) to NIR, deep tissue penetration (up to centimeters), and tunable dosage by adjusting laser irradiation. Successful glucose metabolic regulation has been demonstrated both in vitro and in vivo, thus offering the possibility of developing new alternative strategies to meet the clinical challenges in the treatment of type 2 diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available